Department of Diabetes, Monash University, Melbourne, Australia.
Adv Chronic Kidney Dis. 2021 Jul;28(4):282-289. doi: 10.1053/j.ackd.2021.07.001.
The pathobiology of diabetic kidney disease (DKD) involves an interplay between all the many different cell types that exist within the kidney and their shared and cumulative dysfunction in response to chronic hyperglycemia. DKD is characteriszed by morphological changes including tubular hypertrophy, podocyte dysfunction, mesangial expansion and mesangiolysis, endothelitis and capillary rarefaction, arteriolar hyalinosis, basement membrane thickening, and ultimately nephron dropout and tubulointerstitial fibrosis. These adaptive but ultimately maladaptive changes accelerate the progression of lesions in the diabetic kidney by increasing mechanical and oxidative stress, hypoxia, fibrogenesis, inflammation, senescence, and apoptosis. In particular, atrophy at the critical junction between Bowman's capsule and the proximal tubule likely represent the leading cause of nephron dropout and kidney function decline in DKD. Preventing, slowing, or reversing these changes should be the target of future "smart" therapies for patients with DKD, many of which are now under development.
糖尿病肾病(DKD)的发病机制涉及肾脏内所有不同细胞类型之间的相互作用,以及它们对慢性高血糖的共同和累积功能障碍。DKD 的特征是形态学改变,包括肾小管肥大、足细胞功能障碍、肾小球系膜扩张和溶解、内皮炎和毛细血管稀疏、小动脉玻璃样变、基底膜增厚,最终导致肾小球滤过率下降和肾小管间质纤维化。这些适应性但最终适应性不良的变化通过增加机械和氧化应激、缺氧、纤维化、炎症、衰老和细胞凋亡来加速糖尿病肾脏病变的进展。特别是,在鲍曼囊和近端小管之间的关键连接处的萎缩可能代表 DKD 中肾小球滤过率下降和肾功能下降的主要原因。预防、减缓或逆转这些变化应该是 DKD 患者未来“智能”治疗的目标,目前许多治疗方法正在开发中。